계명대학교 의학도서관 Repository

Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea

Metadata Downloads
Author(s)
SC KimTY AhnHK ChoiNG ChoiTG ChungWS ChungTK HwangJS HyunGW JungCI KimJJ KimSW KimCH LeeKS LeeWH LeeKS MinKH MoonJS PaickKS ParkNC ParkYK ParkJK SeoKK SeoJS ShinYR YoonWC Lee
Keimyung Author(s)
Kim, Chun Il
Department
Dept. of Urology (비뇨의학)
Journal Title
International Journal of Impotence Research
Issued Date
2000
Volume
12
Issue
2
Abstract
A Korean multicenter study was conducted to assess the effectiveness of transurethral alprostadil
with MUSE in 334 subjects with chronic erectile dysfunction (ED) who were enrolled in 21 clinical
centers. Patients with psychogenic impotence comprised about 30% of subjects. Intraurethral
alprostadil was titrated in a stepwise fashion in the clinics from 250 to 500 or 1000 mcg based on
erectile response and tolerability. The erectile responses were evaluated using an erection
assessment scale (score of 1±5). The dose that produced a maximal penile response of score 5 (full
rigid erection) or 4 (full tumescence, partial rigidity) was selected for home treatment. Patients
who showed partial erection (score of 3) with 1000 mcg were also included in the home-treatment
group.
In-clinic phase: 198 men (59.3%) had maximal penile responses of score 4 or 5. The rate of
maximal responses was not related to patient age, etiology or duration of the ED. A total of 228
(68.3%) men progressed to home treatment. The overall level of comfort of the transurethral
alprostadil was rated as uncomfortable or very uncomfortable in 12%. Home phase: During the
two-month period of home treatment, 178 (78.1%) men had successful sexual intercourse at least
once, and 78.2% of administrations (1976) resulted in successful intercourse. The main causes of
drop-out were insuf®cient erectile response in 27 men (11.8%), adverse reactions (mostly penile or
urethral pain) in 7 (3.1%) or both in 7 (3.1%).
In conclusion, transurethral alprostadil could be a suitable treatment option for patients with ED
regardless of age and etiology of ED. Ef®cacy in an Asian population (Korea) is comparable to that
reported previously in Caucasians. International Journal of Impotence Research (2000) 12,
97±101.
Keywords: transurethral alprostadil; erectile dysfunction; ef®cacy; safety
Introduction
Intracavernous injection of vasoactive medication
has been used successfully for over 10 years for the
treatment of erectile dysfunction (ED).1,2 Despite the
ef®cacy of intracavernous pharmacotherapy, longterm
dropout rate with time is high.3±5 One of the
main reasons
Keimyung Author(s)(Kor)
김천일
Publisher
School of Medicine
Citation
SC Kim et al. (2000). Multicenter study of the treatment of erectile dysfunction with
transurethral alprostadil (MUSE) in Korea. International Journal of Impotence Research, 12(2), 97–101.
Type
Article
ISSN
0955-9930
Source
https://www.nature.com/articles/3900490
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/35985
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Urology (비뇨의학)
공개 및 라이선스
  • 공개 구분공개
  • 엠바고Forever
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.